共 129 条
[1]
Crawford J(1991)Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer N Engl J Med 18 164-170
[2]
Ozer H(1993)Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy Eur J Cancer 29A 319-324
[3]
Stoller R(2002)Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology Blood 100 2303-2320
[4]
Johnson D(1998)Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study J Clin Oncol 16 3412-3425
[5]
Lyman G(2001)Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2875-2882
[6]
Tabbara I(2003)A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 29-35
[7]
Kris M(2002)Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 727-731
[8]
Grous J(2002)Initial experience with darbepoetin alfa administered at a fixed dose of 200 mcg every 2 weeks (Q2W) in anemic cancer patients undergoing chemotherapy [abstract] Blood Proc 100 18b-36
[9]
Picozzi V(2002)Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia Oncol 10 31-276
[10]
Rausch G(2002)Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy Br J Cancer 87 268-2034